Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 5,880 shares of the firm’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $13.68, for a total value of $80,438.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) opened at 14.10 on Friday. Momenta Pharmaceuticals Inc. has a one year low of $7.86 and a one year high of $18.26. The firm’s market capitalization is $972.29 million. The firm has a 50-day moving average price of $12.27 and a 200 day moving average price of $11.65.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. The company earned $299.14 million during the quarter, compared to analysts’ expectations of $25.68 million. During the same period last year, the firm earned ($0.44) EPS. The firm’s revenue for the quarter was up 2067.7% on a year-over-year basis. Equities analysts forecast that Momenta Pharmaceuticals Inc. will post ($1.16) earnings per share for the current fiscal year.
Several research analysts have recently issued reports on the company. Zacks Investment Research cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 5th. JPMorgan Chase & Co. dropped their target price on Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. Aegis began coverage on Momenta Pharmaceuticals in a report on Tuesday. They set a “hold” rating and a $15.00 target price on the stock. Maxim Group reaffirmed a “sell” rating and set a $6.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, November 3rd. Finally, Barclays PLC raised Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $13.00 to $19.00 in a report on Tuesday, October 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $16.10.
Several hedge funds have recently bought and sold shares of MNTA. Dynamic Technology Lab Private Ltd acquired a new stake in Momenta Pharmaceuticals during the second quarter valued at approximately $109,000. PNC Financial Services Group Inc. boosted its stake in Momenta Pharmaceuticals by 2.9% in the second quarter. PNC Financial Services Group Inc. now owns 169,060 shares of the biotechnology company’s stock valued at $1,826,000 after buying an additional 4,791 shares in the last quarter. Prudential Financial Inc. boosted its stake in Momenta Pharmaceuticals by 1.9% in the first quarter. Prudential Financial Inc. now owns 147,062 shares of the biotechnology company’s stock valued at $1,359,000 after buying an additional 2,700 shares in the last quarter. Swiss National Bank boosted its stake in Momenta Pharmaceuticals by 2.1% in the second quarter. Swiss National Bank now owns 113,700 shares of the biotechnology company’s stock valued at $1,228,000 after buying an additional 2,300 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its stake in Momenta Pharmaceuticals by 115.4% in the second quarter. BNP Paribas Arbitrage SA now owns 19,816 shares of the biotechnology company’s stock valued at $214,000 after buying an additional 10,617 shares in the last quarter. 81.62% of the stock is owned by institutional investors and hedge funds.
About Momenta Pharmaceuticals